Log in to save to my catalogue

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in...

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_854ec664b1264a5fb5b8d52cbc7969f0

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort

About this item

Full title

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort

Publisher

England: BioMed Central Ltd

Journal title

BMC infectious diseases, 2005-07, Vol.5 (1), p.58-58, Article 58

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

The risk of hepatotoxicity associated with different highly active antiretroviral therapy (HAART) regimens (containing multiple-protease inhibitors, single-protease inhibitors or non nucleoside reverse transcriptase inhibitors) in HIV-HCV co-infected patients has not been fully assessed.
Retrospective analysis of a prospective cohort of 1,038 HI...

Alternative Titles

Full title

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_854ec664b1264a5fb5b8d52cbc7969f0

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_854ec664b1264a5fb5b8d52cbc7969f0

Other Identifiers

ISSN

1471-2334

E-ISSN

1471-2334

DOI

10.1186/1471-2334-5-58

How to access this item